Share
Journal Information
Special content about coronavirus SARS-CoV-2 (COVID-19) in Hematology, Transfusion and Cell Therapy
EXPRESSÃO DO RECEPTOR TOLL- LIKE 2 (TLR2), IRF7 E SERPINF COMO MARCADORES DE PROGNÓSTICO DESFAVORÁVEL EM PACIENTES COM SÍNDROME RESPIRATÓRIA AGUDA DECORRENTE DE INFECÇÃO POR COVID-19
DP Borges, LHJ Silveira, RTG Oliveira, DB Porto, BA Beltrão, MA Viana, JVC Goes, RDB Dias, SMM Magalhães, RF Pinheiro
10.1016/j.htct.2023.09.1543
Hematol Transfus Cell Ther. 2023;45 Supl 4:S857
Full text access
INVESTIGAÇÃO DO POLIMORFISMO -413A>T (RS2071746) NO PROMOTOR DO GENE DA HEME-OXIGENASE 1 EM PACIENTES COM COVID-19
GA Pedroso, AE Alagbe, BB Oliveira, DF Teófilo, E Costa, GAF Maia, DM Albuquerque, FF Costa, MF Sonati, MNND Santos
10.1016/j.htct.2023.09.232
Hematol Transfus Cell Ther. 2023;45 Supl 4:S87
Full text access
Comparison of characteristics and laboratory tests of COVID-19 hematological patients from France and Brazil during the pre-vaccination period: identification of prognostic profiles for survival
Lilith Faucheux, Lucas Bassolli de Oliveira Alves, Sylvie Chevret, Vanderson Rocha
10.1016/j.htct.2022.05.003
Hematol Transfus Cell Ther. 2023;45:306-16
Full text access
Evaluation of lymphocyte count, T-cell subsets and neutrophil-to-lymphocyte ratio as early predictors for severity and outcome of COVID-19 disease–a report from a highly complex hospital in Brazil
Douglas Câmara de Oliveira, Beatriz Sanada Spiri, Yara Carolina Schluga, Julie Lilian Pimentel Justus, Francisco Diego Negrão Lopes Neto, Ana Paula de Azambuja
10.1016/j.htct.2022.05.007
Hematol Transfus Cell Ther. 2023;45:330-7
Full text access
Autoimmune hemolytic anemia and COVID-19 vaccination
Jeremy W. Jacobs
10.1016/j.htct.2022.08.007
Hematol Transfus Cell Ther. 2023;45:410-1
Full text access
Effects of therapeutic plasma exchange on a cohort of patients with severe coronavirus infection: real world evidence from Brazil
Paula Menezes Schiefferdecker, Iara Buselato Chen, Fernanda Bronzel Bher, Leonardo Klettenberg Aciolli, Geovana Bodanese, Lucas Miyake Okumura, Paulo Tadeu Rodrigues de Almeida
10.1016/j.htct.2023.01.004
Hematol Transfus Cell Ther. 2023;45 Supl 2:S148-52
Full text access
EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCRN BLOCKER, IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA): ENERGY PHASE 2/3 STUDY DESIGN
I Murakhovskaya, B Fattizzo, D Cueto, AB Perdomo, M Jouvin
10.1016/j.htct.2022.09.019
Hematol Transfus Cell Ther. 2022;44 Supl 2:S11
Open access
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN PATIENTS WITH SICKLE CELL DISEASE
KH Kuo, A Oluyadi, H Shao, S Morris, AU Zaidi, EJV Beers, SL Thein
10.1016/j.htct.2022.09.021
Hematol Transfus Cell Ther. 2022;44 Supl 2:S12-3
Open access
PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RRBN Presenter, N Shah, A Alencar, J Gerson, M Patel, W Jurczak, K Patel, A Mato, C Cheah, M Wang
10.1016/j.htct.2022.09.214
Hematol Transfus Cell Ther. 2022;44 Supl 2:S127
Open access
PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RR Barreto, K Patel, C Coombs, N Shah, T Eyre, W Wierda, P Ghia, M Davids, W Jurczak, A Mato
10.1016/j.htct.2022.09.235
Hematol Transfus Cell Ther. 2022;44 Supl 2:S139-40
Open access
Publish in
Hematology, Transfusion and Cell Therapy
Hematology, Transfusion and Cell Therapy is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.
www.publicationethics.org.